Phase
Condition
Liver Disease
Wilson's Disease
Kidney Failure
Treatment
UX701
Placebo
Clinical Study ID
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Key Inclusion Criteria:
Confirmed diagnosis of Wilson disease
Stable Wilson disease as evidenced by ongoing copper chelator (ie, penicillamine,trientine) and/or zinc therapy for at least 6 months at screening, with nomedication or dose changes for at least 6 months at screening.
Ongoing restriction of high copper containing foods for at least 6 months atScreening, continued through study participation.
Willing and able to comply with all study procedures and requirements, includingfrequent blood collection, total urine collection over a 24-hour period,patient-reported outcome assessments, and long-term follow-up
Exclusion
Key Exclusion Criteria:
Detectable pre-existing antibodies to the AAV9 capsid.
Stage 1 only: History of copper chelator or zinc therapy noncompliance, in theInvestigator's judgment, within 6 months prior to Screening.
History of liver transplant.
Decompensated hepatic cirrhosis or presence of advanced liver disease as evidencedby portal hypertension, ascites, splenomegaly, esophageal varices, hepaticencephalopathy.
Significant hepatic inflammation as evidenced by laboratory abnormalities.
Model for End-Stage Liver Disease (MELD) score > 13.
Hemoglobin < 9 g/dL
Presence of Stage 3 or higher chronic kidney disease based on estimated glomerularfiltration rate < 60 mL/min/1.73 m2.
Marked neurological deficit or compromise that, in the Investigator's opinion, wouldinterfere with the subject's safety or ability to participate in the study.
Moderate to severe depression, recent or active suicidal ideation with intent orsuicidal behavior, psychosis, or unstable psychiatric illness.
Participation in another gene transfer study or use of another gene transfer productbefore or during study participation.
Subjects with known hypersensitivity to amide-containing local anesthetics areexcluded from participating in the optional liver biopsy substudy.
Note: Other protocol defined Inclusion/ Exclusion criteria may apply
Study Design
Study Description
Connect with a study center
Gordon and Leslie Diamond Health Care Centre
Vancouver, British Columbia V5Z 1M9
CanadaSite Not Available
Centro Hospitalar Universitário Lisboa Norte
Lisboa, Lisbon 1649-035
PortugalSite Not Available
Centro Hospitalar Universitário de São João
Porto, 4200-319
PortugalSite Not Available
Hospital Universitario Vall d'Hebron - PPDS
Barcelona, 08035
SpainSite Not Available
Hospital Universitari i Politecnic La Fe de Valencia
Valencia, 46026
SpainSite Not Available
Kings College NHS Foundation
London, Surrey SE5 9RS
United KingdomSite Not Available
University of California Los Angeles
Los Angeles, California 90095
United StatesSite Not Available
Stanford University
Redwood City, California 94063
United StatesSite Not Available
University of California Davis
Sacramento, California 95817-1348
United StatesSite Not Available
University of Miami
Miami, Florida 33124
United StatesSite Not Available
Northwestern University
Chicago, Illinois 60611
United StatesSite Not Available
Indiana University
Indianapolis, Indiana 46202
United StatesSite Not Available
Massachusetts General Hospital
Boston, Massachusetts 02114
United StatesSite Not Available
University of Michigan
Ann Arbor, Michigan 48109
United StatesSite Not Available
Duke University Medical Center
Durham, North Carolina 27710
United StatesSite Not Available
Vanderbilt University Medical Center
Nashville, Tennessee 37212-2700
United StatesSite Not Available
University of Utah
Salt Lake City, Utah 84132
United StatesSite Not Available
University of Virginia
Charlottesville, Virginia 22908-0001
United StatesSite Not Available
Seattle Children's Hospital
Seattle, Washington 98105
United StatesSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.